Ciloa is currently developping in preclinical phase, 2 candidates against Chikungunya virus (FUI granted) and Zika. These candidate vaccines are virus-free and adjuvant-free.
These first prototypes will validate Ciloa’s platform of a new generation of vaccines. In case of pandemic, this will be a unique tool to develop efficient preventive vaccines on time.
Learn more about our Chikungunya vaccine candidate, co-financed by FEDER.
Thus, current technologies are not well-adapted to pregnant women & immuno-compromised people.
The benefits to use Ciloa’s recombinant exosomes
Ciloa has the sole technology that enables to develop safe & intelligent vaccines based on recombinant exosomes.
Exosomes are known to activate immune responses through various mechanisms, including transfering antigens to dendritic cells, presentating antigens to T lymphocytes, and activating natural killer cells.
In addition, several functional co-stimulatory molecules naturally present on exosomes are able to enhance immune responses. Thus, exosomes presenting antigens trigger efficient protection without any added adjuvants.
No pathogens are necessary to develop vaccines against tumor cells, viruses, bacteria or parasites using membrane proteins (GPCRs, viral envelope proteins …) sorted with their native conformation on exosomes.
The combination of both, a perfect antigen and a potent natural adjuvant effect leads to the perfect candidate vaccine.
As cell-free nanovesicules that do not require the use of a viral machinery for assembly, exosome-based vaccines offer a high bio-safety profile. The scale-up of exosome based vaccines for clinical assays, has been already reported.